Ask AI
Optimizing Outcomes in EBC

CE / CME

Optimizing Outcomes in Early Breast Cancers: A Call To Action

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: March 12, 2026

Expiration: September 11, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following is a key actionable strategy that can be used to mitigate disparities in timely diagnosis and improve access to guideline-concordant care and clinical trials for Black patients with early breast cancer (EBC)?

2.

A 56-year-old postmenopausal woman is diagnosed with node-positive, high-risk estrogen receptor (ER)–positive/HER2-negative EBC. She has completed surgery and adjuvant chemotherapy. Germline BRCA1/2 testing is negative.

Which of the following would you recommend for this patient?

3.

A 49-year-old woman with cT2N2M0 (stage IIIA) hormone receptor (HR)–positive/HER2-positive breast cancer receives neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab. At surgery, she is found to have residual invasive disease in the breast and 3 positive axillary lymph nodes (ypT1cN2).

Based on emerging evidence and current guideline recommendations, what would you offer this patient?